Manufacturer: Pharmaqo Labs
Pharmaceutical name: Stenabolic
Pack: 1 pack (60 caps (15 mg))
SR9009, commonly referred to as “Stenabolic,” is not categorized as a SARM; it is actually a Rev-ErbA ligand. This compound was developed by Professor Thomas Burris at the Scripps Research Institute to help individuals suffering from metabolic disorders, including muscle wasting and cardiovascular issues.
SR9009 acts as an “exercise mimetic” by activating the protein ‘Rev-erb-α,’ which plays a key role in regulating oxidative functions in cells and energy production in mitochondria. Researchers in the medical field are optimistic about using these Rev-erb-α agonists to tackle challenges such as chronic obesity and congestive heart failure.
By modifying protein levels, Stenabolic simulates the effects of physical exercise, boosting mitochondrial functionality within muscle tissue. The compound promotes the production of new mitochondria in cells while eliminating damaged ones, leading to increased energy levels through a rejuvenation process.
SR9009 is an excellent option for a cutting cycle, aiding in fat loss. Additionally, Stenabolic can serve as a highly effective stacking agent alongside other SARMs.
Reviews suggest that Stenabolic is a powerful substance, requiring only minimal doses to achieve a significant biological effect. However, one drawback of SR9009 is its short half-life. With a half-life of just 4 hours, it diminishes from the bloodstream rapidly.
For any drug to function effectively, it is essential to maintain a consistent serum level over time. Consequently, if the compound leaves your system every 4 hours, your body will struggle to sustain an active dose.